Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofpironium bromide gel for clozapine-induced hypersalivation in treatment-resistant schizophrenia
jRCTs041210033Completed
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of sofpironium in schizophrenia and clozapine-induced hypersalivation (CIS) (2 arms). Primary endpoint: Saliva volume per minute at 6 weeks. Started Jul 2021; status: completed.
02
Drugs
sofpironium
03
Conditions
schizophreniaclozapine-induced hypersalivation (CIS)
Beyond the preview
Go deeper on jRCTs041210033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210033.